Use of a sweet whey containing infant formula for promoting the postnatal neuronal development of the infant gastrointestinal tract, and the establishment of the intestinal functions that it controls
The present invention relates to administration of sweet whey protein (SWP) for promoting the enteric neuronal development in infants, especially preterm, low birth, very low and extremely low birth weight infants as well as in young children up until the age of six. Administration of the SWP according to the invention prevents and treats disorders associated with an immature or impaired enteric nervous system. The disorders are, notably, dysfunctional gastrointestinal motility manifested as slow intestinal transit, intestinal discomfort, hard stools, constipation and/or gastrointestinal reflux, gut barrier dysfunction, food intolerance or necrotizing enterocolitis.
1. A method of treating a disorder associated with an immature or impaired enteric nervous system in a young mammal in need thereof, the method comprising administering to the young mammal an effective amount of a composition comprising sweet whey protein in an amount of between 30 wt. % and 80 wt. % of the total protein in the composition, the disorder is selected from the group consisting of (i) gut barrier dysfunction, (ii) food intolerance, (iii) necrotizing enterocolitis, (iv) dysfunctional gastrointestinal motility manifested as at least one of slow intestinal transit, intestinal discomfort, hard stools, constipation or gastrointestinal reflux, and (v) combinations thereof.
2. The method according to claim 1 , wherein the sweet whey protein comprises at least 88% w/w protein relative to the sweet whey protein and has a maximum fat content of 0.2% w/w relative to the sweet whey protein and a caseino-glyco-macropeptide (CGMP) content up to 40% w/w relative to the sweet whey protein.
3. The method according to claim 1 , wherein the sweet whey protein is a modified sweet whey protein (MSWP) from which caseino-glyco-macropeptide (CGMP) has been partially or entirely removed.
4. The method according to claim 3 wherein the final CGMP content of the MSWP is less than 15% w/w.
5. The method according to claim 1 , wherein the sweet whey protein has a degree of hydrolysis of at least 2%.
6. The method according to claim 1 , wherein the young mammal is an animal.
7. The method according to claim 1 , wherein the young mammal is selected from the group consisting of a human foetus, a pre-term or term-born infant, and a child up to the age of six.
8. The method according to claim 7 , wherein administration period to the fetus has a duration of at least one week, and wherein the administration period to the infant or the child has a duration of at least 4 weeks.
9. The method according to claim 1 , wherein the young mammal has at least one characteristic selected from the group consisting of (i) the young mammal experienced hypoxemia-ischemia at birth, (ii) the young mammal has experienced or is experiencing an intrauterine growth retardation (IUGR), (iii) the young mammal had or is predicted to have a low, very low or extremely low birth weight, and (iv) the young mammal is suffering or suffered from enteric nervous system growth retardation in utero, during or after birth.
10. The method according to claim 1 , wherein administration to the young mammal is by a route selected from the group consisting of (i) indirectly via the lactating mother and (ii) directly to the young mammal.
11. The method according to claim 1 , wherein the sweet whey protein is administered directly to the young mammal in a form selected from the group consisting of pure form, diluted in water or breast milk, a food supplement, a milk fortifier, a milk support used during trophic feeding, an infant formula for premature infants, a starter formula, a follow-on formula, a growing-up milk, and a milk based drink.
12. The method according to claim 1 , wherein administration is orally.
13. The method according to claim 1 , wherein the sweet whey protein is administered to the young mammal as a dose of 1.6-3.2 g protein/100 kcal of the composition.
14. The method according to claim 1 , wherein the composition comprises at least one prebiotic.
15. The method according to claim 1 , wherein the composition comprises at least one probiotic.
16. The method according to claim 1 , wherein the composition is administered in a daily dose comprising an amount of the sweet whey protein that is 60 to 80 wt. % of the total protein intake of the young mammal.
17. The method according to claim 1 , wherein the sweet whey protein is between about 70 wt. % and 80 wt. % of the total protein in the composition.
18. The method according to claim 1 , wherein the sweet whey protein has a degree of hydrolysis between 2 and 20%.